ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2401

Disease Activity (DAS-28CRP) In Rheumatoid Arthritis Correlates With Synovial Expression Of Tumor-Associated and IL-6-Dependent Genes

Bernard Lauwerys1, Julie Ducreux2, Adrien Nzeusseu Toukap1, Valérie Badot3, Frédéric A. Houssiau2 and Patrick Durez1, 1Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 2Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 3Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: pathogenesis and synovitis, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: The molecular mechanisms that regulate disease activity in rheumatoid arthritis (RA) are unknown. Using high-throughput transcriptomic data sets generated in knee synovial biopsies from patients with RA, we wanted to identify which probe sets display the highest levels of correlation with disease activity (DAS-28CRP values), and whether they cluster in specific molecular pathways.

Methods: We retrieved gene expression data obtained after hybridization of 65 synovial biopsy samples using GeneChip HGU133Plus2.0 microarrays. 21 of them originated from untreated RA patients. Paired samples were obtained in 12 of these patients, 3 months after initiation of tocilizumab therapy, and in another 8 patients, 3 months after initiation of methotrexate therapy. The last samples were obtained in methotrexate- and TNF blockade-resistant patients before (n=12) and 3 months (n=12) after administration of rituximab therapy. Correlation coefficients were calculated between normalized expression values of each probe set (n = 51,452) and DAS28-CRP among the samples.

Results: When the analyses were performed on all samples, we found that 1,304 probe sets display a >0.50 correlation coefficient with DAS-28CRP values. Strikingly, almost the totality of these probe sets are IL-6 dependent, since they are down-regulated in synovial tissue after administration of tocilizumab.

In a previous study, we found that tocilizumab, rituximab and methotrexate therapies preferentially target IL-6-dependent genes in the synovium. Therefore, correlation studies between gene expression and DAS-28CRP values, performed before and after administration of these treatments, presumably result in a bias favorable to these genes. We therefore performed our correlation study on 21 synovial biopsy samples from untreated patients with RA and active disease. In this case, we found that 393 probe sets display a > 0.50 correlation coefficient with DAS-28CRP values. 15% of them are significantly down-regulated by tocilizumab therapy in the synovium, however, the probe sets with the highest correlation coefficients (between 0.65 and 0.75: GADD45B, TACSTD2, PDE4D, …) are associated with chromatin remodeling, regulation of cell cycle and tumor progression in cancer tissues.

Conclusion: Our data indicate that two distinct sets of transcripts are associated with disease activity (expressed as DAS-28CRP values) in the RA synovium. Immunohistochemistry experiments are ongoing in order to identify which synovial cells express these IL-6-dependent- versus tumor progression-associated transcripts.


Disclosure:

B. Lauwerys,
None;

J. Ducreux,
None;

A. Nzeusseu Toukap,
None;

V. Badot,
None;

F. A. Houssiau,
None;

P. Durez,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-das-28crp-in-rheumatoid-arthritis-correlates-with-synovial-expression-of-tumor-associated-and-il-6-dependent-genes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology